Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 9NET 6CNS 6Gastrointestinal 3Head & Neck 2Genitourinary 2Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × gallium Ga 68 dotatate × Tumor-Agnostic × Clear all
NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡